A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Able and willing to sign the informed consent form
• Patients with a diagnosis of atopic dermatitis and disease for at least 1 year
• Moderate to severe atopic dermatitis
Locations
United States
California
Ctr for Dermatology Clinical Res
RECRUITING
Fremont
New Jersey
Care Access Hoboken
RECRUITING
Hoboken
Other Locations
Canada
Novartis Investigative Site
RECRUITING
Toronto
Singapore
Novartis Investigative Site
RECRUITING
Singapore
Novartis Investigative Site
RECRUITING
Singapore
Novartis Investigative Site
RECRUITING
Singapore
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
1-888-669-6682
Backup
Novartis Pharmaceuticals
+41613241111
Time Frame
Start Date: 2025-11-10
Estimated Completion Date: 2027-09-13
Participants
Target number of participants: 84
Treatments
Experimental: GIA632
Active treatment arm
Placebo_comparator: Placebo
Placebo treatment arm
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals